Formulation issues

Dermal Absorption and Toxicity Assessment, Second Edition

Volumn , Issue , 2007, Pages 117-134

  Schaefer, U F ^a   Lippold, B C ^b   Leopold, C S ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056919000     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (136)

1. Tronnier H. Arzneitherapie an der Haut. Pharm Ztg 1977; 45:2021-7.
2. Lippold BC. How to optimize drug penetration through the skin. Pharm Acta Helv 1992; 67:294-300.
3. Schiller M, Schmidt PC. Transdermale therapeutische Systeme-Arzneistoffe zum Aufkleben. Pharm Ztg 2002; 22:18-24.
4. Moser K, Kriwet K, Fröhlich C, et al. Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug. Pharm Res 2001; 18:1006-11.
5. Moser K, Kriwet K, Naik A, et al. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 2001; 52:103-12.
6. Moser K, Kriwet K, Fröhlich C, et al. Permeation enhancement of a highly lipophilic drug using supersaturated systems. J Pharm Sci 2001; 90:605-14.
7. Leopold CS. Enhancer-Effekte von lipophilen Salbengrundstoffen auf die Steady-State-Penetration von Methylnicotinat durch die Haut. PhD Thesis, University of Düsseldorf, 1992.
8. Bach M, Lippold BC. Percutaneous penetration enhancement and its quantification. Eur J Pharm Biopharm 1998; 46:1-13.
9. Lippold BC, Reimann H. Wirkungsbeeinflussung bei Lösungssalben durch Vehikel am Beispiel von Methylnicotinat. Teil I: relative thermodynamische aktivität des Arzneistoffs in verschiedenen Vehikeln und Freisetzungsverhalten. Acta Pharm Technol 1989; 35:136-9.
10. Iervolino M, Raghavan SL, Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 2000; 198:229-38.
11. Moser K, Kriwet K, Kalia YN, et al. Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery. Int J Pharm 2001; 224:169-76.
12. Raghavan SL, Kiepfer B, Davis AF, et al. Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. Int J Pharm 2001; 221:95-105.
13. Iervolino M, Cappello B, Raghavan SL, et al. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm 2001; 212:131-41.
14. Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987; 6:85-97.
15. Suhonen TM, Bouwstra JC, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release 1999; 59:149-61.
16. Wotton PK, Mollgaard B, Hadgraft JW, et al. Vehicle effect on topical drug delivery. III:effect of azone on the cutaneous permeation of metronidazole and propylene glycol. Int J Pharm 1985; 24:19-26.
17. Vaddi HK, Ho PC, Chan SY. Terpenes in propylene glycol as skin-penetration enhancers: permeation and partition of haloperidol, fourier transform infrared spectroscopy, and differential scanning calorimetry. J Pharm Sci 2002; 91:1639-51.
18. Potts RO, Francoeur ML. The influence of stratum corneum morphology on water permeability. J Invest Dermatol 1991; 96:495-9.
19. Hadgraft J. Modulation of the barrier function of the skin. Skin Pharmacol Appl Skin Physiol 2001; 14:72-81.
20. Loth H. Vehicular influence on transdermal drug penetration. Int J Pharm 1991; 68:1-10.
21. Hadgraft J. Skin deep. Eur J Pharm Biopharm 2004; 58:291-9.
22. Yamane MA, Williams AC, Barry BW. Effects of terpenes and oleic acid as skin penetration enhancers towards 5-fluorouracil as assessed with time; permeation, partitioning and differential scanning calorimetry. Int J Pharm 1995; 116:237-51.
23. Pilgram GSK, van der Meulen J, Gorris GS, et al. The influence of two azones and sebaceous lipids on the lateral organization of lipids isolated from human stratum corneum. Biochim Biophys Acta 2001; 1511:244-54.
24. Barry BW. Lipid-protein-partitioning theory of skin penetration enhancement. J Control Release 1991; 15:237-48.
25. Bouwstra JA, Pilgram G, Gooris GS, et al. New aspects of the skin barrier organization. Skin Pharmacol Appl Skin Physiol 2001; 14:52-62.
26. Akimoto T, Aoyagi T, Minoshima J, et al. Polymeric percutaneous drug penetration enhancer: synthesis and enhancing property of PEG/PDMS block copolymer with a cationic end group. J Control Release 1997; 49:229-41.
27. Godwin DA, Michniak BB. Influence of drug lipophilicity on terpenes as transdermal penetration enhancers. Drug Dev Ind Pharm 1999; 25:905-15.
28. Cornwell PA, Barry BW. Effects of penetration enhancer treatment on the statistical distribution of human skin permeabilities. Int J Pharm 1995; 117:101-12.
29. Smith EW, Maibach HI. Percutaneous Penetration Enhancers. Boca Raton, FL: CRC Press, 1995.
30. Wilhelm KP, Surber C, Maibach HI. Effect of sodium lauryl sulfate-induced skin irritation on in vivo percutaneous absorption of four drugs. J Invest Dermatol 1991; 96:927-32.
31. Frömder A, Lippold BC. Water vapour transmission and occlusivity in vivo of lipophilic excipients used in ointments. Int J Cosmet Sci 1993; 15:113-24.
32. Anigbogu ANC, Williams AC, Barry BW, et al. Fourier transform raman spectroscopy of interactions between the penetration enhancer dimethyl sulfoxide and human stratum corneum. Int J Pharm 1995; 125:265-82.
33. Puttnam NA. Attenuated total reflectance studies of the skin. J Soc Cosmet Chem 1972; 23:209-26.
34. w CG on the skin accumulation and transdermal permeation of ultraviolet absorbers. Eur J Pharm Biopharm 2002; 53:23-7.
35. w on permeant diffusivity and solubility in human stratum corneum. Pharm Res 1996; 13:542-6.
36. Gwak HS, Oh IS, Chun IK. Transdermal delivery of ondansetron hydrochloride: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm 2004; 30:187-94.
37. Panchagnula R, Ritschel WA. Development and evaluation of an intracutaneous depot formulation of corticosteroids using transcutol as a cosolvent: in-vitro, ex-vitro and in-vivo rat studies. J Pharm Pharmacol 1991; 43:609-14.
38. Touitou E, Levi-Schaffer F, Dayan N, et al. Modulation of caffeine skin delivery by carrier design: liposomes versus penetration enhancers. Int J Pharm 1994; 103:131-6.
39. Yamashita F, Koyama Y, Kitano M, et al. Analysis of in vivo skin penetration enhancement by oleic acid based on two-layer diffusion model with polar and nonpolar routes in the stratum corneum. Int J Pharm 1995; 117:173-9.
40. Cornwell PA, Tubek J, van Gompel HAHP, et al. Glycerol monocaprylate/caprate as a moderate skin penetration enhancer. Int J Pharm 1998; 171:243-55.
41. Wang Y, Fan Q, Song Y, et al. Effects of fatty acids and iontophoresis on the delivery of midodrine hydrochloride and the structure of human skin. Pharm Res 2003; 20:1612-8.
42. Kanikkannan N, Singh M. Skin permeation enhancement effect and skin irritation of saturated fatty alcohols. Int J Pharm 2002; 248:219-28.
43. Tanojo H, Boelsma E, Junginger HE, et al. In vivo human skin permeability enhancement by oleic acid: a laser Doppler velocimetry study. J Control Release 1999; 58:97-104.
44. Stott PW, Williams AC, Barry BW. Mechanistic study into the enhanced transdermal permeation of a model b-blocker, propranolol, by fatty acids: a melting point depression effect. Int J Pharm 2001; 219:161-76.
45. Menon GK. New insights into skin structure: scratching the surface. Adv Drug Deliv Rev 2002; 54:3-17.
46. Green PG, Guy RH, Hadgraft J. In vitro and in vivo enhancement of skin permeation with oleic and lauric acids. Int J Pharm 1988; 48:103-11.
47. Meidan VM, Al-Khalili M, Michniak BB. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int J Pharm 2003; 264:73-83.
48. Tanojo H, Junginger HE, Bodde HE. In vivo skin permeability enhancement by oleic acid: transepidermal water loss and Fourier-transform infrared spectroscopy studies. J Control Release 1997; 47:31-9.
49. Naik A, Pechthold LARM, Potts RO, et al. Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. J Control Release 1995; 37:299-306.
50. Potts RO, Golden GM, Francoeur ML, et al. Mechanism and enhancement of solute transport across the stratum corneum. J Control Release 1991; 15:249-60.
51. Ongpipattanakul B, Burnette RR, Potts RO, et al. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res 1991; 8:350-4.
52. Kurihara-Bergstrom T, Knutson K, DeNoble LJ, et al. Percutaneous absorption enhancement of an ionic molecule by ethanol-water systems in human skin. Pharm Res 1990; 7:762-6.
53. Megrab NA, Williams AC, Barry BW. Oestradiol permeation across human skin, silastic and snake skin membranes: the effects of ethanol/water co-solvent systems. Int J Pharm 1995; 116:101-12.
54. w) on the in vitro percutaneous permeation of sodium lauryl sulfate using human skin. Acta Derm Venereol 1996; 76:182-5.
55. Dias M, Raghavan SL, Hadgraft J. ATR-FTIR spectroscopic investigation on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes. Int J Pharm 2001; 216:51-9.
56. w on the thermal behaviour of human stratum corneum. Int J Pharm 1989; 52:47-54.
57. w, induced fluidity in human stratum corneum. A fourier transform infrared spectroscopy investigation using the perdeuterated analogue. J Control Release 1996; 41:283-90.
58. Degim IT, Uslu A, Hadgraft J, et al. The effects of azone and capsaicin on the permeation of naproxen through human skin. Int J Pharm 1999; 179:21-5.
59. Fang J-Y, Hwang T-L, Fang CL, et al. In vitro and in vivo evaluations of the efficacy and safety of skin permeation enhancers using flurbiprofen as a model drug. Int J Pharm 2003; 255:153-66.
60. Bonina FP, Montenegro L, Scrofani N, et al. Effects of phospholipid based formulations on in vitro and in vivo percutaneous absorption of methyl nicotinate. J Control Release 1995; 34:53-63.
61. Touitou E, Levi-Schaffer F, Shaco-Ezra N, et al. Enhanced permeation of theophylline through the skin and its effect on fibroblast proliferation. Int J Pharm 1991; 70:159-66.
62. Bendas B, Schmalfuß U, Neubert R. Influence of polypropylene glycol as cosolvent on mechanisms of drug transport from hydrogels. Int J Pharm 1995; 116:19-30.
63. Morimoto Y, Sugibayashi K, Hosoya K, et al. Penetration enhancing effect of azone on the transport of 5-fluorouracil across the hairless rat skin. Int J Pharm 1986; 32:31-8.
64. Funk JO, Maibach HI. Propylene glycol dermatitis: re-evaluation of an old problem. Contact Dermatitis 1994; 31:236-41.
65. Gloor M, Hauth A, Gehring W. O/W emulsions compromise the stratum corneum barrier and improve drug penetration. Pharmazie 2003; 58:709-15.
66. Ayala-Bravo HA, Quintanar-Guerrero D, Naik A, et al. Effects of sucrose oleate and sucrose laureate on in vivo human stratum corneum permeability. Pharm Res 2003; 20:1267-73.
67. El-Kattan AF, Asbill CS, Kim N, et al. The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. Int J Pharm 2001; 215:229-40.
68. Arellano A, Santoyo S, Martin C, et al. Enhancing effect of terpenes on the in vitro percutaneous absorption of diclofenac sodium. Int J Pharm 1996; 130:141-5.
69. Cornwell PA, Barry BW, Bouwstra JA, et al. Modes of action of terpene penetration enhancers in human skin; differential scanning calorimetry, small-angle X-ray diffraction and enhancer uptake studies. Int J Pharm 1996; 127:9-26.
70. Mackay KMB, Williams AC, Barry BW. Effect of melting point of chiral terpenes on human stratum corneum uptake. Int J Pharm 2001; 228:89-97.
71. Roemmen C, Leopold CS, Lippold BC. Do local anesthetics have an influence on the percutaneous penetration of a model corticosteroid? An in vivo study using the vasoconstrictor assay Eur J Pharm Sci 1999; 9:227-34.
72. Zatz JL. Percutaneous absorption: computer simulation using multicompartmented membrane models. In:Bronaugh RL, Maibach HI, eds. Percutaneous Absorption. New York: Marcel Dekker, 1985;165-81.
73. Guy RH, Hadgraft J. A theoretical description relating skin penetration to the thickness of the applied medicament. Int J Pharm 1980; 6:321-32.
74. Cooper ER, Berner B. Finite dose pharmacokinetics of skin penetration. J Pharm Sci 1985; 74:1100-2.
75. Zatz JL. Influence of depletion on percutaneous absorption characteristics. J Soc Cosmet Chem 1985; 36:237-49.
76. Addicks WJ, Flynn G, Weiner N, et al. A mathematical model to describe drug release from thin topical applications. Int J Pharm 1989; 56:243-8.
77. Addicks W, Weiner N, Flynn G, et al. Topical drug delivery from thin applications:theoretical predictions and experimental results. Pharm Res 1990; 7:1048-54.
78. Walker M, Chambers LA, Hollingsbee DA, et al. Significance of vehicle thickness to skin penetration of halcinonide. Int J Pharm 1991; 70:167-72.
79. Lippold BC, Teubner A. Biopharmazeutische Qualität von Arzneiformen, insbesondere für lokale Anwendung, abgeleitet aus Wirkungsmessungen. Pharm Ind 1981; 43:71-3.
80. Lippold BC. Selection of the vehicle for topical administration of drugs. Pharm Acta Helv 1984; 59:166-71.
81. Leopold CS. Quantification of depletion in solution-type topical preparations in vivo. J Cosmet Sci 1998; 49:165-74.
82. Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology 2005; 210:157-68.
83. Schulmeister L. Transdermal drug patches: medicine with muscle. Nursing 2005; 35:48-52.
84. Stricker T, Sennhauser FH. Allergic contact dermatitis due to transdermal contraception patch. J Pediatr 2006; 148:845.
85. Hadgraft J, Lane ME. Passive transdermal drug delivery systems: recent considerations and advances. Am J Drug Deliv 2006; 4:153-60.
86. Foroutan SM, Ettehadi HA, Torabi HR. Formulation and in vitro evaluation of silver sulfadiazine spray. Iran J Pharm Res 2002; 1:47-9.
87. Eaglstein WH, Sullivan TP, Giordano PA, Miskin BM. A liquid adhesive bandage for the treatment of minor cuts and abrasions. Dermatol Surg 2002; 28:263-7.
88. Campbell K, Woodbury MG, Whittle H, Labate T, Hoskin A. A clinical evaluation of 3M no sting barrier film. Ostomy Wound Manage 2000; 46(1):24-30.
89. Misra A, Pal R, Majumdar SS, Talwar GP, Singh O. Biphasic testosterone delivery profile observed with two different transdermal formulations. Pharm Res 1997; 14(9):1264-8.
90. Zurdo Schroeder I, Franke P, Schaefer UF, Lehr CM. Development and characterization of film forming polymeric solutions for skin drug delivery. Eur J Pharm Biopharm 2007; 65(1):111-21.
91. Zurdo Schroeder I, Franke P, Schaefer UF, Lehr CM. Poster presentation. CRS, Annual Meeting, Vienna, 2006.
92. Mezei M, Gulasekharam V. Liposomes-a selective drug delivery system for the topical route of administration. I. Lotion dosage form. Life Sci 1980; 26:1473-7.
93. Mezei M, Gulasekharam V. Liposomes. A selective drug delivery system for the topical route of administration: gel dosage form. J Pharm Pharmacol 1982; 34:473-4.
94. Korting HC, Zienicke H, Schäfer-Korting M, Braun-Falco O. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 1990; 39(4):349-51.
95. Schaefer-Korting M, Korting HC, Ponce-Poschl E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin Invest 1994; 72:1086-91.
96. Touitou E, Shaco-Ezra N, Dayan N, Jushynski M, Rafaeloff R, Azoury R. Dyphylline liposomes for delivery to the skin. J Pharm Sci 1992; 81:131-4.
97. Touitou E, Levi-Schaffer F, Dayan N, et al. Modulation of caffeine skin delivery by carrier design: liposomes versus permeation enhancers. Int J Pharm 1994; 103:131-6.
98. Foldvari M. In vitro cutaneous and percutaneous delivery and in vivo efficacy of tetracaine from liposomal and conventional vehicles. Pharm Res 1994; 11:1593-8.
99. Egbaria K, Ramachandran C, Weiner N. Topical delivery of ciclosporin: evaluation of various formulations using in vitro diffusion studies in hairless mouse skin. Skin Pharmacol 1990; 3(1):21-8.
100. Short SM, Rubas W, Paasch BD, Mrsny RJ. Transport of biologically active interferongamma across human skin in vitro. Pharm Res 1995; 12(8):1140-5.
101. Lieb LM, Flynn G, Weiner N. Follicular (pilosebaceous unit) deposition and pharmacological behavior of cimetidine as a function of formulation. Pharm Res 1994; 11(10):1419-23.
102. Lieb LM, Ramachandran C, Egbaria K, Weiner N. Topical delivery enhancement with multilamellar liposomes into pilosebaceous units: I. In vitro evaluation using fluorescent techniques with the hamster ear model. J Invest Dermatol 1992; 99(1):108-13.
103. Weiner N, Lieb L, Niemiec S, Ramachandran C, Hu Z, Egbaria K. Liposomes: a novel topical delivery system for pharmaceutical and cosmetic applications. J Drug Target 1994; 2:405-10.
104. Hofland HE, van der Geest R, Bodde HE, Junginger HE, Bouwstra JA. Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in vitro. Pharm Res 1994; 11(5):659-64.
105. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release 1994; 30:1-15.
106. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta Biomembr 1992; 1104:226-32.
107. w. Biochim Biophys Acta Biomembr 2003; 1614:156-64.
108. Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta Biomembr 2004; 1663:61-73.
109. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes-Novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65:403-18.
110. Horwitz E, Pisanty S, Czerninski R, Helser M, Eliav E, Touitou E. A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87(6):700-5.
111. Dayan N, Touitou E. Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes. Biomaterials 2000; 21(18):1879-85.
112. Esposito E, Menegatti E, Cortesi R. Ethosomes and liposomes as topical vehicles for azelaic acid: a preformulation study. J Cosmet Sci 2004; 55(3):253-64.
113. Rao YF, Li F, Liang WQ. Study on transdermal permeation and skin accumulation of finasteride ethosomes. Chin Pharm J 2004; 39(12):923-5.
114. Godin B, Touitou E, Rubinstein E, Athamna A, Athamna M. A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: an in vivo study. J Antimicrob Chemother 2005; 55(6):989-94.
115. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release 2005; 106:99-110.
116. Maia CS, Mehnert W, Schaefer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 2000; 196:165-7.
117. Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin a loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49(3):211-8.
118. Wissing SA, Mueller RH. A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int J Cosmet Sci 2001; 23(4):233-43.
119. Wissing SA, Mueller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release 2002; 81(3):225-33.
120. Yener G, Inceguel T, Yener N. Importance of using solid lipid microspheres as carriers for UV filters on the example octyl methoxy cinnamate. Int J Pharm 2003; 258:203-7.
121. Chen H, Chang X, Du D, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006; 110(2):296-306.
122. Mueller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54(Suppl.):S131-55.
123. Ricci M, Puglia C, Bonina F, Di Giovanni C, Giovagnoli S, Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC):in vitro and in vivo studies. J Pharm Sci 2005; 94:1149-59.
124. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release 2004; 97(3):477-84.
125. Lademann J, Richter H, Schaefer UF, et al. Hair follicles-a long-term reservoir for drug delivery. Skin Pharmacol Physiol 2006; 19(4):232-6.
126. Alvarez-Román R, Naik A, Kalia YN, Fessi H, Guy RH. Visualization of skin penetration using confocal laser scanning microscopy. Eur J Pharm Biopharm 2004; 58:301-16.
127. Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004; 21:1818-25.
128. Alvarez-Román R, Naik A, Kalia YN, Guy RN, Fessi H. Skin penetration and distribution of polymeric nanoparticles. J Control Release 2004; 99(1):53-62.
129. Luengo J, Weiss B, Schneider M, et al. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol 2006; 19:190-7.
130. Stracke F, Weiss B, Lehr CM, König K, Schaefer UF, Schneider M. Multiphoton microscopy for the investigation of dermal penetration of nanoparticle-borne drugs. J Invest Dermatol 2006; 126:2224-33.
131. Hammond SA, Tsonis C, Sellins K, et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 2000; 43(1):45-55.
132. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization:T cell responses and boosting of existing immunity. Vaccine 2001; 19:2701-7.
133. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm 2004; 275:13-7.
134. Lademann J, Weigmann H, Rickmeyer C, et al. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol 1999; 12:247-56.
135. Pflücker F, Wendel V, Hohenberg H, et al. The human stratum corneum layer: an effective barrier against dermal uptake of different forms of topically applied micronised titanium dioxide. Skin Pharmacol Appl Skin Physiol 2001; 14(Suppl. 1):92-7.
136. Gamer AO, Leibold E, Van Ravenzwaay B. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol In Vitro 2006; 20(3):301-7.